Solution Biologics Sdn. Bhd. ("SOLBIO") has entered into a market authorisation , manufacturing and commercialisation agreement with CanSino Biologics Inc.based in Tianjin, China ("CanSinoBIO", SHSE:688185, HKEX:06185) for the supply of vaccines especially the Covid-19 vaccine into Malaysia. As part of the manufacturing agreement , SOLBIO is in the process of establishing a Fill & Finish Facility in our current building at Technology Park Malaysia. We are also responsible to market the vaccine,co-developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB). to the ASEAN countries namely Philippines , Thailand, Singapore, Myanmar , Vietnam , Cambodia , Laos and Brunei .
Biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market.
Since biologics are quite large in comparison to chemical-based drugs and made up of proteins, they require extra care to maintain their size, shape, form, and stability. These factors correlate to the intended effect and efficiency of the biologic drug.
In the area of vaccines, there's no doubt that immunization saves millions of lives every year from vaccine-preventable diseases and one of the success stories in global health. More than 20 life-threatening diseases can now be prevented by immunization, and new vaccines for major killers like meningitis, cervical cancer, cholera and influenza are now being introduced in many countries. Today, vaccination is increasingly protecting health among people of all ages.
With the incorporation of Solution Biologics Sdn. Bhd., as a biopharmaceutical company, SGB will enter into the life sciences business and will work to deliver vaccines and biologics that will help millions in Malaysiaand the ASEAN region.
We are committed to developing newer and more effective vaccines and biologics through research and development programme with our partners. Our plan for the future will include paediatric and adult vaccines that are part of the National Immunisation Schedule of Malaysia and the Extended Programme of Immunisation (EPI) of various countries in the region.
Incorporated in 2009, CanSinoBIO (SHSE:688185, HKEX:06185) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine approved in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector). Additional information can be found online at www.cansinotech.com.
